Breast cancer is the most common cancer among women. Absence of hormone receptors (estrogen and progesterone) and lack of overexpression of Human Epidermal Growth Factor 2 (HER2) make triple-negative breast cancer (TNBC) an aggressive subtype of breast cancer that is resistant to conventional therapies. Peptide decoys have emerged as a novel therapeutic approach for the treatment of breast cancer. Decoy peptide technology entails the use of soluble proteins or peptides, including binding proteins or inactive cell surface receptors. Peptide decoys bind to certain ligands (e.g., inflammatory cytokines) with high affinity and specificity as receptors but cannot initiate any signaling pathway that is involved in the pathogenesis of breast cancer. In this review, we discuss the use of decoy peptides as a novel therapeutic approach for breast cancer treatment.

中文翻译：

---

肽诱饵：一种为乳腺癌提供治疗机会的新技术。

乳腺癌是女性中最常见的癌症。激素受体（雌激素和孕激素）的缺失和人类表皮生长因子 2 (HER2) 的过度表达使三阴性乳腺癌 (TNBC) 成为一种侵袭性乳腺癌亚型，对常规疗法具有抗性。肽诱饵已成为治疗乳腺癌的新型治疗方法。诱饵肽技术需要使用可溶性蛋白质或肽，包括结合蛋白或非活性细胞表面受体。肽诱饵以高亲和力和特异性作为受体与某些配体（例如，炎性细胞因子）结合，但不能启动任何参与乳腺癌发病机制的信号通路。在这次审查中，